PL3746126T3 - Sposoby i kompozycje do leczenia bezdechu sennego lub zwykłego chrapania - Google Patents

Sposoby i kompozycje do leczenia bezdechu sennego lub zwykłego chrapania

Info

Publication number
PL3746126T3
PL3746126T3 PL19705634.4T PL19705634T PL3746126T3 PL 3746126 T3 PL3746126 T3 PL 3746126T3 PL 19705634 T PL19705634 T PL 19705634T PL 3746126 T3 PL3746126 T3 PL 3746126T3
Authority
PL
Poland
Prior art keywords
snoring
compositions
ordinary
treatment
methods
Prior art date
Application number
PL19705634.4T
Other languages
English (en)
Inventor
Lawrence G. Miller
Barry Wohl
Walter J. Lunsmann
Original Assignee
Apnimed, Inc. (Delaware)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed, Inc. (Delaware) filed Critical Apnimed, Inc. (Delaware)
Publication of PL3746126T3 publication Critical patent/PL3746126T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19705634.4T 2018-01-30 2019-01-30 Sposoby i kompozycje do leczenia bezdechu sennego lub zwykłego chrapania PL3746126T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862623892P 2018-01-30 2018-01-30
PCT/US2019/015781 WO2019152475A1 (en) 2018-01-30 2019-01-30 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
PL3746126T3 true PL3746126T3 (pl) 2024-12-16

Family

ID=65441079

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19705634.4T PL3746126T3 (pl) 2018-01-30 2019-01-30 Sposoby i kompozycje do leczenia bezdechu sennego lub zwykłego chrapania

Country Status (27)

Country Link
US (6) US11911351B2 (pl)
EP (2) EP3746126B1 (pl)
JP (3) JP7422666B2 (pl)
KR (2) KR20250156197A (pl)
CN (2) CN118384147A (pl)
AU (2) AU2019214891B2 (pl)
BR (1) BR112020015316A2 (pl)
CA (1) CA3089712A1 (pl)
DK (1) DK3746126T3 (pl)
EA (1) EA202091597A1 (pl)
ES (1) ES2991425T3 (pl)
FI (1) FI3746126T3 (pl)
HR (1) HRP20241412T1 (pl)
HU (1) HUE068505T2 (pl)
IL (1) IL276247A (pl)
LT (1) LT3746126T (pl)
MA (1) MA52861B1 (pl)
MD (1) MD3746126T2 (pl)
MX (2) MX2020008086A (pl)
PL (1) PL3746126T3 (pl)
PT (1) PT3746126T (pl)
RS (1) RS66104B1 (pl)
SG (1) SG11202007226UA (pl)
SI (1) SI3746126T1 (pl)
SM (1) SMT202400400T1 (pl)
UA (1) UA129618C2 (pl)
WO (1) WO2019152475A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018260666B2 (en) 2017-04-28 2022-07-21 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
EP4635514A3 (en) 2019-02-08 2025-12-24 The Brigham & Women's Hospital, Inc. Methods and compositions for treating sleep apnea
WO2021091902A1 (en) * 2019-11-04 2021-05-14 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
CN116391233A (zh) * 2020-09-30 2023-07-04 皇家飞利浦有限公司 用于执行剂量滴定的方法和系统
WO2022187420A1 (en) * 2021-03-04 2022-09-09 Apnimed, Inc. (Delaware) Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
GEAP202416361A (en) * 2021-03-24 2024-04-25 Apnimed Inc Delaware Methods and compositions for treating sleep apnea
WO2022235726A1 (en) 2021-05-04 2022-11-10 Apnimed, Inc. (Delaware) Solid forms of (r)-oxybutynin d-malate
KR20240021920A (ko) * 2021-06-17 2024-02-19 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제
US20250049779A1 (en) 2021-12-22 2025-02-13 Bayer Aktiengesellschaft Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
MX2024007767A (es) 2021-12-22 2024-07-04 Bayer Ag Combinacion de un antagonista del adrenoceptor a2 subtipo c (alfa-2c) con un antagonista del receptor muscarinico para el tratamiento de la apnea del sue?o.
US20250302814A1 (en) * 2022-05-13 2025-10-02 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
KR20250000641A (ko) * 2023-06-27 2025-01-03 주식회사 아스트로젠 수면장애 및/또는 수면장애 관련 질환을 예방, 개선 또는 치료하는 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (pl) 1960-07-26
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES2268712T3 (es) 1995-10-24 2007-03-16 Grunenthal Gmbh Montirelina para inhibir la apnea del sueño.
PT1257277E (pt) 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
US20020155113A1 (en) 2001-03-13 2002-10-24 Miyoung Chun Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function
US20030060513A1 (en) 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20040235925A1 (en) 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20050009862A1 (en) 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
SG133606A1 (en) 2003-12-22 2007-07-30 Acadia Pharm Inc Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060039867A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2006055854A2 (en) 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
KR20070087678A (ko) 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
CA2646729A1 (en) 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence
CA2603920A1 (en) 2005-04-15 2006-10-26 The Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US20070021322A1 (en) 2005-07-21 2007-01-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Selective resonance of chemical structures
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
ES2610508T3 (es) 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
WO2008122019A1 (en) 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
EP2455076A1 (en) 2007-04-09 2012-05-23 Sepracor Inc. Compositions comprising desvenlafaxine for use in treating sleep-related breathing disorders
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US20090048233A1 (en) 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination
CN101925349A (zh) 2007-12-21 2010-12-22 欧兰德股份有限公司 替马西泮的口腔崩解片组合物
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
CN102939008A (zh) 2010-04-01 2013-02-20 塞拉维达公司 改善睡眠质量的方法
CA2825309C (en) 2011-01-28 2019-10-01 Pfantastic Medical Research Institute, Llc Pyridostigmine for the treatment of obstructive sleep apnea
JP2012176958A (ja) 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
US20160008334A1 (en) 2013-03-05 2016-01-14 Requis Pharmaceuticals Inc. Preparations for the Treatment of Sleep-Related Respiratory Disorders
WO2016062279A1 (zh) 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 苹果酸丙氯陪拉辛锭用于制备治疗癌症药物的用途
DK3288946T3 (da) 2015-04-27 2019-11-25 Arena Pharm Inc 5-ht2c-receptoragonister og sammensætninger og anvendelsesfremgangsmåder
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
US20180235934A1 (en) 2015-08-18 2018-08-23 Massachusetts Institute Of Technology Noradrenergic drug treatment of obstructive sleep apnea
AU2018260666B2 (en) * 2017-04-28 2022-07-21 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
MX2020007876A (es) 2018-01-31 2020-12-03 Res Inst Nationwide Childrens Hospital Terapia genica para la distrofia muscular de cinturas tipo 2c.
EP4635514A3 (en) 2019-02-08 2025-12-24 The Brigham & Women's Hospital, Inc. Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
RS66104B1 (sr) 2024-11-29
KR20250156197A (ko) 2025-10-31
AU2019214891A1 (en) 2020-08-20
SMT202400400T1 (it) 2024-11-15
AU2024227631A1 (en) 2024-11-14
CA3089712A1 (en) 2019-08-08
HUE068505T2 (hu) 2024-12-28
EP4445951A3 (en) 2025-01-08
JP7422666B2 (ja) 2024-01-26
US20210038541A1 (en) 2021-02-11
CN118384147A (zh) 2024-07-26
EA202091597A1 (ru) 2020-10-22
SG11202007226UA (en) 2020-08-28
JP2021516218A (ja) 2021-07-01
ES2991425T3 (es) 2024-12-03
US11911351B2 (en) 2024-02-27
EP4445951A2 (en) 2024-10-16
MD3746126T2 (ro) 2024-12-31
MA52861A (fr) 2021-05-05
AU2019214891B2 (en) 2024-08-01
US20260027070A1 (en) 2026-01-29
US20220378724A1 (en) 2022-12-01
KR20200115598A (ko) 2020-10-07
US20250186371A1 (en) 2025-06-12
SI3746126T1 (sl) 2025-01-31
US20240156753A1 (en) 2024-05-16
MX2024001713A (es) 2024-02-20
IL276247A (en) 2020-09-30
UA129618C2 (uk) 2025-06-18
EP3746126A1 (en) 2020-12-09
FI3746126T3 (fi) 2024-10-10
JP2023181322A (ja) 2023-12-21
DK3746126T3 (da) 2024-10-07
HRP20241412T1 (hr) 2024-12-20
WO2019152475A1 (en) 2019-08-08
PT3746126T (pt) 2024-10-21
MX2020008086A (es) 2021-02-15
EP3746126B1 (en) 2024-07-31
CN111670050A (zh) 2020-09-15
LT3746126T (lt) 2024-10-25
MA52861B1 (fr) 2024-09-30
BR112020015316A2 (pt) 2020-12-08
NZ766673A (en) 2025-08-29
KR102874891B1 (ko) 2025-10-21
US20240390299A1 (en) 2024-11-28
JP2025159230A (ja) 2025-10-17

Similar Documents

Publication Publication Date Title
PL3746126T3 (pl) Sposoby i kompozycje do leczenia bezdechu sennego lub zwykłego chrapania
ZA201907158B (en) Methods and compositions for treating sleep apnea
GB201501983D0 (en) Treatment of snoring and sleep apnoea
EP3866736A4 (en) METHODS AND DEVICES FOR THE TREATMENT OF SLEEP APNEA
EP3572400A4 (en) EZH2 INHIBITOR AND ITS USE
EP3844178C0 (en) VACCINE INTENDED FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE
EP3641754A4 (en) COMPOSITIONS AND TREATMENTS AGAINST SLEEP DISORDERS
DK4014976T3 (da) Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan
PL3500287T3 (pl) Kompozycja zawierająca samoorganizujące się peptydy do stosowania do leczenia zapalenia przyzębia i/lub zapalenia tkanek okołowszczepowych
EP3920898C0 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF SLEEP APNEA
PL3810128T3 (pl) Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek
EP3677265A4 (en) COMPOSITION TO PREVENT OR TREAT SLEEP DISORDERS
PL3823623T3 (pl) Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemu
EP4338751C0 (en) COMBINATION OF SEPETAPROST AND NETARSUDIL FOR USE IN THE PROPHYLAXIS OR TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION
EP3541185C0 (en) USE OF 2-HYDROXYBENZYLAMINE IN THE TREATMENT AND PREVENTION OF PULMONARY HYPERTENSION
DK3937949T3 (da) Phytoecdysoner og derivater deraf til anvendelse i behandlingen af ændret respiratorisk funktion
EP3746068A4 (en) COMPOSITIONS AND METHODS OF TREATMENT FOR OBSTRUCTIVE SLEEP APNEA
EP3749354A4 (en) NEW COMPOSITION AND ITS USE
HUE062748T2 (hu) Kompozíció hajnövekedési rendellenességek megelõzésére és kezelésére
EP3713590C0 (en) BETA 2 HUMAN DEFENSIN FOR USE IN THE PREVENTION AND TREATMENT OF GRAFT-VERSE-HOST DISEASE
IL261984B (en) Sultiame for the treatment of sleep apnea
IL307186A (en) Methods and preparations for treating sleep apnea
EP3621945C0 (en) STILBENE DERIVATIVES FOR USE IN THE TREATMENT OF CNS DISORDERS AND OTHER DISORDERS
IL288949A (en) Lemborexant for treating sleep issues
GB201913589D0 (en) Systems and methods for reducing snoring and/or sleep apnea